Correction to "Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study" [The Lancet Regional Health - Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366.

[This corrects the article DOI: 10.1016/j.lana.

Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study.

Background: COVID-19 vaccines have proven safe and efficacious in reducing severe illness and death. Cuban protein subunit vaccine Abdala has shown safety, tolerability and efficacy (92·3% [95% CI: 85·7‒95·8]) against SARS-CoV-2 in clinical trials. This study aimed to estimate Abdala's real-world vaccine effectiveness (VE).

[Approaches, evolution and coping with the demographic aging in CubaAbordagens, evolução e enfrentamento do envelhecimento demográfico em Cuba].

The demographic aging in Cuba has caused considerable changes in mortality and morbidity; its growing trend and high speed affect the attention of the elderly, posing a challenge to public health. This article focuses on years 1950-2015, and aims to present the situation of this population phenomenon from a positive view, according to three aspects: aging as an achievement, challenge and development opportunity; demographic and epidemiological transitions; and policies and strategies to address aging. The general fertility rate has decreased from 4.